CORCEPT THERAPEUTICS INC (1CORT.MI) Stock Price, Forecast & Analysis
Europe • Euronext Milan • BIT:1CORT • US2183521028
1CORT.MI Key Statistics, Chart & Performance
The current stock price of 1CORT.MI is 38.02 EUR.
1CORT.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1CORT.MI.
1CORT.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to 1CORT.MI. 1CORT.MI gets an excellent profitability rating and is at the same time showing great financial health properties.
1CORT.MI Financial Highlights
Over the last trailing twelve months 1CORT.MI reported a non-GAAP Earnings per Share(EPS) of 0.98. The EPS increased by 9.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.55% | ||
| ROA | 15.83% | ||
| ROE | 19.61% | ||
| Debt/Equity | 0 |
1CORT.MI Forecast & Estimates
For the next year, analysts expect an EPS growth of 13.31% and a revenue growth 29.78% for 1CORT.MI
1CORT.MI Ownership
1CORT.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.69 | 197.812B | ||
| SAN | SANOFI | 9.51 | 195.855B | ||
| SNW | SANOFI | 9.58 | 195.638B | ||
| MRK | MERCK KGAA | 14.13 | 53.065B | ||
| UCB | UCB SA | 25.28 | 52.168B | ||
| UNC | UCB SA | 25.68 | 51.37B | ||
| BAYN | BAYER AG-REG | 9.37 | 44.027B | ||
| 1BAYN | BAYER AG-REG | 9.17 | 44.008B | ||
| IPN | IPSEN | 11.93 | 11.365B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.104B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find more growth stocks the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1CORT.MI
Company Profile
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. The company is headquartered in Redwood City, California and currently employs 500 full-time employees. The company went IPO on 2004-04-15. The firm is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Company Info
CORCEPT THERAPEUTICS INC
101 Redwood Shores Parkway
Redwood City CALIFORNIA US
Employees: 500
Phone: 16506888803
CORCEPT THERAPEUTICS INC / 1CORT.MI FAQ
What does 1CORT do?
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. The company is headquartered in Redwood City, California and currently employs 500 full-time employees. The company went IPO on 2004-04-15. The firm is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Can you provide the latest stock price for CORCEPT THERAPEUTICS INC?
The current stock price of 1CORT.MI is 38.02 EUR. The price decreased by -39.36% in the last trading session.
Does 1CORT stock pay dividends?
1CORT.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1CORT stock?
1CORT.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists 1CORT stock?
1CORT.MI stock is listed on the Euronext Milan exchange.
What is the Price/Earnings (PE) ratio of CORCEPT THERAPEUTICS INC (1CORT.MI)?
The PE ratio for CORCEPT THERAPEUTICS INC (1CORT.MI) is 38.8. This is based on the reported non-GAAP earnings per share of 0.98 and the current share price of 38.02 EUR.
Can you provide the growth outlook for CORCEPT THERAPEUTICS INC?
The Revenue of CORCEPT THERAPEUTICS INC (1CORT.MI) is expected to grow by 29.78% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.